Literature DB >> 9609418

Severe hyperthermia during tetrabenazine therapy for tardive dyskinesia.

E Stevens1, A Roman, M Houa, D Razavi, N Jaspar.   

Abstract

We recently observed a 45-year-old patient with a history of psychiatric illness who presented with severe hyperthermia (rectal temperature above 41 degrees C) with intense rhabdomyolysis and liver cytolysis during tetrabenazine therapy for neuroleptic tardive dyskinesia. In addition to tetrabenazine, this patient took lorazepam and two antidepressant drugs: clomipramine, a potent serotonin-reuptake inhibitor, and mianserin. Hyperthermia responded to parenteral sodium dantrolene and oral bromocriptine administration. The significant role of tetrabenazine (a central nervous system dopamine-depleting drug) and the contribution of antidepressants to the mechanism of this neuroleptic malignant syndrome - like hyperthermia are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9609418     DOI: 10.1007/s001340050583

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  10 in total

1.  Neuroleptic malignant syndrome: a unique association with a tricyclic antidepressant.

Authors:  L Baca; L Martinelli
Journal:  Neurology       Date:  1990-11       Impact factor: 9.910

2.  Long-term effects of tetrabenazine in hyperkinetic movement disorders.

Authors:  J Jankovic; J Beach
Journal:  Neurology       Date:  1997-02       Impact factor: 9.910

3.  Serotonin syndrome due to an overdose of moclobemide and clomipramine. A potentially life-threatening association.

Authors:  B François; P Marquet; A Desachy; J Roustan; G Lachatre; H Gastinne
Journal:  Intensive Care Med       Date:  1997-01       Impact factor: 17.440

4.  Tetrabenazine as a cause of neuroleptic malignant syndrome.

Authors:  M Ossemann; C J Sindic; C Laterre
Journal:  Mov Disord       Date:  1996-01       Impact factor: 10.338

5.  A case of tetrabenazine-induced neuroleptic malignant syndrome after prolonged treatment.

Authors:  G M Petzinger; S B Bressman
Journal:  Mov Disord       Date:  1997-03       Impact factor: 10.338

6.  Prospective evaluation of the serotonin syndrome in depressed inpatients treated with clomipramine.

Authors:  M Lejoyeux; F Rouillon; J Adès
Journal:  Acta Psychiatr Scand       Date:  1993-11       Impact factor: 6.392

7.  Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease.

Authors:  R E Burke; S Fahn; R Mayeux; H Weinberg; K Louis; J H Willner
Journal:  Neurology       Date:  1981-08       Impact factor: 9.910

8.  Neuroleptic malignant syndrome related to tetrabenazine introduction and haloperidol discontinuation in Huntington's disease.

Authors:  D Mateo; J L Muñoz-Blanco; S Giménez-Roldán
Journal:  Clin Neuropharmacol       Date:  1992-02       Impact factor: 1.592

9.  Serotonin syndrome.

Authors:  R A Bodner; T Lynch; L Lewis; D Kahn
Journal:  Neurology       Date:  1995-02       Impact factor: 9.910

10.  The pharmacokinetics of tetrabenazine and its hydroxy metabolite in patients treated for involuntary movement disorders.

Authors:  M S Roberts; S McLean; K S Millingen; H M Galloway
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  10 in total
  3 in total

1.  Clomipramine induced neuroleptic malignant syndrome and pyrexia of unknown origin.

Authors:  Alison M Haddow; Dawn Harris; Martin Wilson; Hannah Logie
Journal:  BMJ       Date:  2004-12-04

Review 2.  Tourette's syndrome and role of tetrabenazine: review and personal experience.

Authors:  Mauro Porta; Marco Sassi; Mario Cavallazzi; Maurizio Fornari; Arianna Brambilla; Domenico Servello
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

3.  Risk of Neuroleptic Malignant Syndrome with Vesicular Monoamine Transporter Inhibitors.

Authors:  Stanley N Caroff
Journal:  Clin Psychopharmacol Neurosci       Date:  2020-05-31       Impact factor: 2.582

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.